Matrix metalloproteinases and their tissue inhibitors in hypertension-related pregnancy complications

Journal of Human Hypertension

Volumn 27, Issue 2, 2013, Pages 72-78

  Karthikeyan, V J ^a   Lane, D A ^a   Beevers, D G ^a   Lip, G Y H ^a   Blann, A D ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

eclampsia; extracellular matrix; matrix metalloproteinase 9; pre eclampsia; pregnancy; tissue inhibitor of metalloproteinase 1

Indexed keywords

COLLAGENASE; GELATINASE; GELATINASE A; GELATINASE B; MATRILYSIN; MATRIX METALLOPROTEINASE; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ANGIOGENESIS; CYTOTROPHOBLAST; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; FEMALE; GENE LOCATION; HUMAN; MATERNAL HYPERTENSION; MOLECULAR WEIGHT; PREECLAMPSIA; PREGNANT WOMAN; PROTEINURIA; REPRODUCTION; REVIEW; SEIZURE; ZYMOGRAPHY;

ECLAMPSIA; FEMALE; HUMANS; MATRIX METALLOPROTEINASES; PRE-ECLAMPSIA; PREGNANCY; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 84872142016     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2012.8     Document Type: Review

References (104)

1. Lijnen HR. Plasmin and matrix metalloproteinases in vascular remodeling. Thromb Haemost 2001; 86: 324-333. (Pubitemid 32663963)
2. Kugler A. Matrix metalloproteinases and their inhibitors. Anticancer Res 1999; 19: 1589-1592. (Pubitemid 29255653)
3. Sang QX. Complex role of matrix metalloproteinases in angiogenesis. Cell Res 1998; 8: 171-177. (Pubitemid 128544277)
4. Birkedal-Hansen H, Moore WG, Bodden MK, Windsor LJ, Birkedal-Hansen B, DeCarlo A et al. Matrix metalloproteinases: A review. Crit Rev Oral Biol Med 1993; 4: 197-250. (Pubitemid 23103292)
5. Derosa G, D'Angelo A, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo S et al. Matrix metalloproteinase-2,-9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension. Endothelium 2006; 13: 227-231. (Pubitemid 44110588)
6. Tan J, Hua Q, Xing X, Wen J, Liu R, Yang Z. Impact of the metalloproteinase-9/ tissue inhibitor of metalloproteinase-1 system on large arterial stiffness in patients with essential hypertension. Hypertens Res 2007; 30: 959-963. (Pubitemid 350120974)
7. Franz M, Berndt A, Altendorf-Hofmann A, Fiedler N, Richter P, Schumm J et al. Serum levels of large tenascin-C variants, matrix metalloproteinase-9, and tissue inhibitors of matrix metalloproteinases in concentric versus eccentric left ventricular hypertrophy. Eur J Heart Fail 2009; 11: 1057-1062.
8. Ahmed SH, Clark LL, Pennington WR, Webb CS, Bonnema DD, Leonardi AH et al. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: Relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation 2006; 113: 2089-2096.
9. Heymans S, Schroen B, Vermeersch P, Milting H, Gao F, Kassner A et al. Increased cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 is related to cardiac fibrosis and dysfunction in the chronic pressure-overloaded human heart. Circulation 2005; 112: 1136-1144. (Pubitemid 41216120)
10. Elmas E, Lang S, Dempfle CE, Kalsch T, Hannak D, Sueselbeck T et al. High plasma levels of tissue inhibitor of metalloproteinase-1 (TIMP-1) and interleukin-8 (IL-8) characterize patients prone to ventricular fibrillation complicating myocardial infarction. Clin Chem Lab Med 2007; 45: 1360-1365. (Pubitemid 47557078)
11. Newby AC, Southgate KM, Davies M. Extracellular matrix degrading metalloproteinases in the pathogenesis of arteriosclerosis. Basic Res Cardiol 1994; 89 (Suppl 1): 59-70. (Pubitemid 24314598)
12. Kadoglou NP, Daskalopoulou SS, Perrea D, Liapis CD. Matrix metalloproteinases and diabetic vascular complications. Angiology 2005; 56: 173-189. (Pubitemid 40404472)
13. Sheppard SJ, Khalil RA. Risk factors and mediators of the vascular dysfunction associated with hypertension in pregnancy. Cardiovasc Hematol Disord Drug Targets 2010; 10: 33-52.
14. Montagnana M, Lippi G, Albiero A, Scevarolli S, Salvagno GL, Franchi M et al. Evaluation of metalloproteinases 2 and 9 and their inhibitors in physiologic and pre-eclamptic pregnancy. J Clin Lab Anal 2009; 23: 88-92.
15. Tayebjee MH, Karalis I, Nadar SK, Beevers DG, MacFadyen RJ, Lip GY. Circulating matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases-1 and-2 levels in gestational hypertension. Am J Hypertens 2005; 18: 325-329. (Pubitemid 40409911)
16. Van Lint P, Libert C. Chemokine and cytokine processing by matrix metalloproteinases and its effect on leukocyte migration and inflammation. J Leukoc Biol 2007; 82: 1375-1381. (Pubitemid 350276947)
17. Opdenakker G, Van den Steen PE, Dubois B, Nelissen I, Van Coillie E, Masure S et al. Gelatinase B functions as regulator and effector in leukocyte biology. J Leukoc Biol 2001; 69: 851-859. (Pubitemid 32577883)
18. Shapiro SD, Kobayashi DK, Ley TJ. Cloning and characterization of a unique elastolytic metalloproteinase produced by human alveolar macrophages. J Biol Chem 1993; 268: 23824-23829. (Pubitemid 23335353)
19. Pendas AM, Knauper V, Puente XS, Llano E, Mattei MG, Apte S et al. Identification and characterization of a novel human matrix metalloproteinase with unique structural characteristics, chromosomal location, and tissue distribution. J Biol Chem 1997; 272: 4281-4286. (Pubitemid 27078499)
20. Kolb C, Mauch S, Peter HH, Krawinkel U, Sedlacek R. The matrix metalloproteinase RASI-1 is expressed in synovial blood vessels of a rheumatoid arthritis patient. Immunol Lett 1997; 57: 83-88. (Pubitemid 27319317)
21. Denhardt DT, Feng B, Edwards DR, Cocuzzi ET, Malyankar UM. Tissue inhibitor of metalloproteinases (TIMP, aka EPA): Structure, control of expression and biological functions. Pharmacol Ther 1993; 59: 329-341. (Pubitemid 23344435)
22. Khokha R, Waterhouse P. The role of tissue inhibitor of metalloproteinase-1 in specific aspects of cancer progression and reproduction. J Neurooncol 1994; 18: 123-127. (Pubitemid 24216047)
23. Nagase H, Suzuki K, Itoh Y, Kan CC, Gehring MR, Huang W et al. Involvement of tissue inhibitors of metalloproteinases (TIMPS) during matrix metalloproteinase activation. Adv Exp Med Biol 1996; 389: 23-31.
24. Raffetto JD, Khalil RA. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol 2008; 75: 346-359. (Pubitemid 350298459)
25. Arthur MJ, Iredale JP, Mann DA. Tissue inhibitors of metalloproteinases: Role in liver fibrosis and alcoholic liver disease. Alcohol Clin Exp Res 1999; 23: 940-943. (Pubitemid 29256587)
26. Shiomi T, Okada Y. MT1-MMP and MMP-7 in invasion and metastasis of human cancers. Cancer Metast Rev 2003; 22: 145-152. (Pubitemid 36561054)
27. Toi M, Ishigaki S, Tominaga T. Metalloproteinases and tissue inhibitors of metalloproteinases. Breast Cancer Res Treat 1998; 52: 113-124. (Pubitemid 29056089)
28. DeClerck YA. Purification and characterization of a collagenase inhibitor produced by bovine vascular smooth muscle cells. Arch Biochem Biophys 1988; 265: 28-37.
29. Apte SS, Mattei MG, Olsen BR. Cloning of the cDNA encoding human tissue inhibitor of metalloproteinases-3 (TIMP-3) and mapping of the TIMP3 gene to chromosome 22. Genomics 1994; 19: 86-90. (Pubitemid 24034370)
30. Apte SS, Olsen BR, Murphy G. The gene structure of tissue inhibitor of metalloproteinases (TIMP)-3 and its inhibitory activities define the distinct TIMP gene family. J Biol Chem 1996; 271: 2874. (Pubitemid 26047911)
31. Weir RA, Clements S, Steedman T, Dargie HJ, McMurray JJ, Squire IB et al. Plasma TIMP-4 predicts left ventricular remodeling after acute myocardial infarction. J Card Fail 2011; 17: 465-471.
32. Meissburger B, Stachorski L, Roder E, Rudofsky G, Wolfrum C. Tissue inhibitor of matrix metalloproteinase 1 (TIMP1) controls adipogenesis in obesity in mice and in humans. Diabetologia 2011; 54: 1468-1479.
33. Kelly D, Squire IB, Khan SQ, Dhillon O, Narayan H, Ng KH et al. Usefulness of plasma tissue inhibitors of metalloproteinases as markers of prognosis after acute myocardial infarction. Am J Cardiol 2010; 106: 477-482.
34. Remacle AG, Shiryaev SA, Radichev IA, Rozanov DV, Stec B, Strongin AY. Dynamic interdomain interactions contribute to the inhibition of matrix metalloproteinases (MMPs) by tissue inhibitors of metalloproteinases (TIMPs). J Biol Chem 2011; 286: 21002-21012.
35. Tamarina NA, McMillan WD, Shively VP, Pearce WH. Expression of matrix metalloproteinases and their inhibitors in aneurysms and normal aorta. Surgery 1997; 122: 264-271.
36. Jung K, Lein M, Ulbrich N, Rudolph B, Henke W, Schnorr D et al. Quantification of matrix metalloproteinases and tissue inhibitors of metalloproteinase in prostatic tissue: Analytical aspects. Prostate 1998; 34: 130-136. (Pubitemid 28080040)
37. Marín F, Roldán V, Climent V, Garcia A, Marco P, Lip GY. Is thrombogenesis in atrial fibrillation related to matrix metalloproteinase-1 and its inhibitor, TIMP-1? Stroke 2003; 34: 1181-1186. (Pubitemid 36547510)
38. Wilson EM, Gunasinghe HR, Coker ML, Sprunger P, Lee-Jackson D, Bozkurt B et al. Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure. J Card Fail 2002; 8: 390-398. (Pubitemid 36055741)
39. Schnaper HW, Grant DS, Stetler-Stevenson WG, Fridman R, D'Orazi G, Murphy AN et al. Type IV collagenase(s) and TIMPs modulate endothelial cell morphogenesis in vitro. J Cell Physiol 1993; 156: 235-246. (Pubitemid 23244085)
40. Miya M, Maeshima A, Mishima K, Sakurai N, Ikeuchi H, Kuroiwa T et al. Enhancement of in vitro human tubulogenesis by endothelial cell-derived factors: Implications for in vivo tubular regeneration after injury. Am J Physiol Renal Physiol 2011; 301: F387-F395.
41. Kemik O, Kemik AS, Sumer A, Dulger AC, Adas M, Begenik H et al. Levels of matrix metalloproteinase-1 and tissue inhibitors of metalloproteinase-1 in gastric cancer. World J Gastroenterol 2011; 17: 2109-2112.
42. Mroczko B, Lukaszewicz-Zajac M, Gryko M, Kêdra B, Szmitkowski M. Clinical significance of serum levels of matrix metalloproteinase 2 (MMP-2) and its tissue inhibitor (TIMP-2) in gastric cancer. Folia Histochem Cytobiol 2011; 49: 125-131.
43. Musia K, Zwolinska D. Matrix metalloproteinases and soluble Fas/FasL system as novel regulators of apoptosis in children and young adults on chronic dialysis. Apoptosis 2011; 16: 653-659.
44. Laviades C, Varo N, Fernández J, Mayor G, Gil MJ, Monreal I et al. Abnormalities of the extracellular degradation of collagen type I in essential hypertension. Circulation 1998; 98: 535-540. (Pubitemid 28371251)
45. Li-Saw-Hee FL, Edmunds E, Blann AD, Beevers DG, Lip GY. Matrix metalloproteinase-9 and tissue inhibitor metalloproteinase-1 levels in essential hypertension. Relationship to left ventricular mass and anti-hypertensive therapy. Int J Cardiol 2000; 75: 43-47.
46. Zervoudaki A, Economou E, Stefanadis C, Pitsavos C, Tsioufis K, Aggeli C et al. Plasma levels of active extracellular matrix metalloproteinases 2 and 9 in patients with essential hypertension before and after antihypertensive treatment. J Hum Hypertens 2003; 17: 119-124. (Pubitemid 36292367)
47. Antoniou GA, Tentes IK, Antoniou SA, Georgiadis GS, Giannoukas AD, Simopoulos C et al. Circulating matrix metalloproteinases and their inhibitors in inguinal hernia and abdominal aortic aneurysm. Int Angiol 2011; 30: 123-129.
48. Mammi C, Sala A, Volterrani M, Gatta L, Antelmi A, Feraco A et al. Exercise training reduces serum capacity to induce endothelial cell death in patients with chronic heart failure. Eur J Heart Fail 2011; 13: 642-650.
49. Yang DC, Ma ST, Tan Y, Chen YH, Li D, Tang B et al. Imbalance of matrix metalloproteinases/tissue inhibitor of metalloproteinase-1 and loss of fibronectin expression in patients with congestive heart failure. Cardiology 2010; 116: 133-141.
50. Okumura Y, Watanabe I, Nakai T, Ohkubo K, Kofune T, Kofune M et al. Impact of biomarkers of inflammation and extracellular matrix turnover on the outcome of atrial fibrillation ablation: Importance of matrix metalloproteinase-2 as a predictor of atrial fibrillation recurrence. J Cardiovasc Electrophysiol 2011; 22: 987-993.
51. Idriss NK, Lip GY, Balakrishnan B, Jaumdally R, Boos CJ, Blann AD. Plasma haemoxygenase-1 in coronary artery disease. A comparison with angiogenin, matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1 and vascular endothelial growth factor. Thromb Haemost 2010; 104: 1029-1037.
52. Brunner S, Kim JO, Methe H. Relation of matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio in peripheral circulating CD14+ monocytes to progression of coronary artery disease. Am J Cardiol 2010; 105: 429-434.
53. Kaireviciute D, Blann AD, Balakrishnan B, Lane DA, Patel JV, Uzdavinys G et al. Characterisation and validity of inflammatory biomarkers in the prediction of post-operative atrial fibrillation in coronary artery disease patients. Thromb Haemost 2010; 104: 122-127.
54. Givvimani S, Tyagi N, Sen U, Mishra PK, Qipshidze N, Munjal C et al. MMP-2/ TIMP-2/TIMP-4 versus MMP-9/TIMP-3 in transition from compensatory hypertrophy and angiogenesis to decompensatory heart failure. Arch Physiol Biochem 2010; 116: 63-72.
55. Kandalam V, Basu R, Abraham T, Wang X, Soloway PD, Jaworski DM et al. TIMP2 deficiency accelerates adverse post-myocardial infarction remodeling because of enhanced MT1-MMP activity despite lack of MMP2 activation. Circ Res 2010; 106: 796-808.
56. Castro MM, Rizzi E, Prado CM, Rossi MA, Tanus-Santos JE, Gerlach RF. Imbalance between matrix metalloproteinases and tissue inhibitor of metalloproteinases in hypertensive vascular remodeling. Matrix Biol 2010; 29: 194-201.
57. Hansson J, Vasan RS, Arnlov J, Ingelsson E, Lind L, Larsson A et al. Biomarkers of extracellular matrix metabolism (MMP-9 and TIMP-1) and risk of stroke, myocardial infarction, and cause-specific mortality: Cohort study. PLoS One 2011; 6: E16185.
58. Velagaleti RS, Gona P, Sundstrom J, Larson MG, Siwik D, Colucci WS et al. Relations of biomarkers of extracellular matrix remodeling to incident cardiovascular events and mortality. Arterioscler Thromb Vasc Biol 2010; 30: 2283-2288.
59. Tayebjee MH, Nadar S, Blann AD, Gareth Beevers D, MacFadyen RJ, Lip GY. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: A substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Am J Hypertens 2004; 17: 764-769. (Pubitemid 39201090)
60. Yasmin, McEniery CM, Wallace S, Dakham Z, Pulsalkar P, Maki-Petaja K et al. Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arterioscler Thromb Vasc Biol 2005; 25: 372.
61. McNulty M, Mahmud A, Spiers P, Feely J. Collagen type-I degradation is related to arterial stiffness in hypertensive and normotensive subjects. J Hum Hypertens 2006; 20: 867-873. (Pubitemid 44614069)
62. Saglam M, Karakaya O, Esen AM, Barutcu I, Dogan S, Karavelioglu Y et al. Contribution of plasma matrix metalloproteinases to development of left ventricular hypertrophy and diastolic dysfunction in hypertensive subjects. Tohoku J Exp Med 2006; 208: 117-122. (Pubitemid 43174163)
63. Ergul A, Portik-Dobos V, Hutchinson J, Franco J, Anstadt MP. Downregulation of vascular matrix metalloproteinase inducer and activator proteins in hypertensive patients. Am J Hypertens 2004; 17: 775-782. (Pubitemid 39201092)
64. Spinale FG. Myocardial matrix remodeling and the matrix metalloproteinases: Influence on cardiac form and function. Physiol Rev 2007; 87: 1285-1342. (Pubitemid 350041472)
65. ACOG technical bulletin. Hypertension in pregnancy. Number 219-January 1996 (replaces no. 91, February 1986). Committee on Technical Bulletins of the American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet 1996; 53: 175-183.
66. National High Blood Pressure Education Program Working Group. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol 2000; 183: S1-S22.
67. Symonds EM. Aetiology of pre-eclampsia: A review. J R Soc Med 1980; 73: 871-875. (Pubitemid 11219444)
68. Page EW. The physiological basis of symptoms in eclampsia. Californ Med 1949; 70: 1-4.
69. Chesley LC. Vascular reactivity in normal and toxemic pregnancy. Clin Obstet Gynecol 1966; 9: 871-881.
70. Lyall F, Greer IA. The vascular endothelium in normal pregnancy and pre-eclampsia. Rev Reprod 1996; 1: 107-116. (Pubitemid 126664713)
71. Meekins JW, McLaughlin PJ, West DC, McFadyen IR, Johnson PM. Endothelial cell activation by tumour necrosis factor-alpha (TNF-alpha) and the development of pre-eclampsia. Clin Exp Immunol 1994; 98: 110-114. (Pubitemid 24315460)
72. Rutherford RA, McCarthy A, Sullivan MH, Elder MG, Polak JM, Wharton J. Nitric oxide synthase in human placenta and umbilical cord from normal, intrauterine growth-retarded and pre-eclamptic pregnancies. Br J Pharmacol 1995; 116: 3099-3109. (Pubitemid 26007754)
73. Zhou Y, Damsky CH, Fisher SJ. Pre-eclampsia is associated with failure of human cytotrophoblasts to mimic a vascular adhesion phenotype. One cause of defective endovascular invasion in this syndrome? J Clin Invest 1997; 99: 2152-2164. (Pubitemid 27203771)
74. Cartwright JE, Fraser R, Leslie K, Wallace AE, James JL. Remodelling at the maternal-fetal interface: Relevance to human pregnancy disorders. Reproduction 2010; 140: 803-813.
75. Harris LK. Review: Trophoblast-vascular cell interactions in early pregnancy: How to remodel a vessel. Placenta 2010; 31(Suppl): S93-S98.
76. Bryant-Greenwood GD. The extracellular matrix of the human fetal membranes: Structure and function. Placenta 1998; 19: 1-11. (Pubitemid 28112055)
77. Wulff C, Weigand M, Kreienberg R, Fraser HM. Angiogenesis during primate placentation in health and disease. Reproduction 2003; 126: 569-577. (Pubitemid 37540616)
78. Huppertz B, Peeters LL. Vascular biology in implantation and placentation. Angiogenesis 2005; 8: 157-167. (Pubitemid 41712845)
79. Karthikeyan VJ, Lip GY, Baghdadi S, Lane DA, Beevers DG, Blann AD. Angiogenin and hemoxygenase in pregnancy: Influence of hypertension. Angiology 2012; 63: 194-198.
80. Lalu MM, Xu H, Davidge ST. Matrix metalloproteinases: Control of vascular function and their potential role in preeclampsia. Front Biosci 2007; 12: 2484-2493.
81. van Hinsbergh VW, Engelse MA, Quax PH. Pericellular proteases in angiogenesis and vasculogenesis. Arterioscler Thromb Vasc Biol 2006; 26: 716-728. (Pubitemid 43732143)
82. Isaka K, Usuda S, Ito H, Sagawa Y, Nakamura H, Nishi H et al. Expression and activity of matrix metalloproteinase 2 and 9 in human trophoblasts. Placenta 2003; 24: 53-64. (Pubitemid 37184696)
83. Sawicki G, Radomski MW, Winkler-Lowen B, Krzymien A, Guilbert LJ. Polarized release of matrix metalloproteinase-2 and-9 from cultured human placental syncytiotrophoblasts. Biol Reprod 2000; 63: 1390-1395.
84. Merchant SJ, Davidge ST. The role of matrix metalloproteinases in vascular function: Implications for normal pregnancy and pre-eclampsia. Br J Obs Gynae 2004; 111: 931-939. (Pubitemid 39223042)
85. Kelly BA, Bond BC, Poston L. Gestational profile of matrix metalloproteinases in rat uterine artery. Mol Hum Reprod 2003; 9: 351-358. (Pubitemid 36748840)
86. Jones RL, Findlay JK, Farnworth PG, Robertson DM, Wallace E, Salamonsen LA. Activin A and inhibin A differentially regulate human uterine matrix metalloproteinases: Potential interactions during decidualization and trophoblast invasion. Endocrinology 2006; 147: 724-732. (Pubitemid 43112988)
87. Dubois B, Arnold B, Opdenakker G. Gelatinase B deficiency impairs reproduction. J Clin Invest 2000; 106: 627-628.
88. Jim B, Sharma S, Kebede T, Acharya A. Hypertension in pregnancy: A comprehensive update. Cardiol Rev 2010; 18: 178-189.
89. Palei AC, Sandrim VC, Cavalli RC, Tanus-Santos JE. Comparative assessment of matrix metalloproteinase (MMP)-2 and MMP-9, and their inhibitors, tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in preeclampsia and gestational hypertension. Clin Biochem 2008; 41: 875-880.
90. Singh M, Kindelberger D, Nagymanyoki Z, Ng SW, Quick CM, Elias KM et al. Matrix metalloproteinases and their inhibitors and inducer in gestational trophoblastic diseases and normal placenta. Gynecol Oncol 2011; 122: 178-182.
91. Narumiya H, Zhang Y, Fernandez-Patron C, Guilbert LJ, Davidge ST. Matrix metalloproteinase-2 is elevated in the plasma of women with preeclampsia. Hypertens Pregnancy 2001; 20: 185-194. (Pubitemid 33032126)
92. Myers JE, Merchant SJ, Macleod M, Mires GJ, Baker PN, Davidge ST. MMP-2 levels are elevated in the plasma of women who subsequently develop preeclampsia. Hypertens Pregnancy 2005; 24: 103-115. (Pubitemid 40911348)
93. Lavee M, Goldman S, Daniel-Spiegel E, Shalev E. Matrix metalloproteinase-2 is elevated in midtrimester amniotic fluid prior to the development of preeclampsia. Reprod Biol Endocrinol 2009; 7: 85-89.
94. de Jager CA, Linton EA, Spyropoulou I, Sargent IL, Redman CW. Matrix metalloprotease-9, placental syncytiotrophoblast and the endothelial dysfunction of pre-eclampsia. Placenta 2003; 24: 84-91. (Pubitemid 37184699)
95. Gallery ED, Campbell S, Arkell J, Nguyen M, Jackson CJ. Preeclamptic decidual microvascular endothelial cells express lower levels of matrix metalloproteinase-1 than normals. Microvasc Res 1999; 57: 340-346. (Pubitemid 29393279)
96. Schipper EJ, Bolte AC, Schalkwijk CG, Van Geijn HP, Dekker GA. TNF-receptor levels in preeclampsia-results of a longitudinal study in high-risk women. J Matern Fetal Neonatal Med 2005; 18: 283-287. (Pubitemid 43062374)
97. Galewska Z, Romanowicz L, Jaworski S, Bankowski E. Gelatinase matrix metalloproteinase (MMP)-2 and MMP-9 of the umbilical cord blood in preeclampsia. Clin Chem Lab Med 2008; 46: 517-522. (Pubitemid 351820348)
98. Galewska Z, Romanowicz L, Jaworski S, Bankowski E. Matrix metalloproteinases, MMP-7 and MMP-26, in plasma and serum of control and preeclamptic umbilical cord blood. Eur J Obstet Gynecol Reprod Biol 2010; 150: 152-156.
99. Fridman R, Toth M, Chvyrkova I, Meroueh SO, Mobeshery S. Cell surface association of matrix metalloproteinase-9 (gelatinase B). Cancer Metastas Rev 2003; 22: 153-166. (Pubitemid 36561055)
100. Anacker J, Segerer SE, Hagemann C, Feix S, Kapp M, Bausch R et al. Human decidua and invasive trophoblasts are rich sources of nearly all human matrix metalloproteinases. Mol Hum Reprod 2011; 17: 637-652.
101. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: Structure, function, and biochemistry. Circ Res 2003; 92: 827-839. (Pubitemid 36542523)
102. Chaudhary AK, Singh M, Bharti AC, Asotra K, Sundaram S, Mehrotra R. Genetic polymorphisms of matrix metalloproteinases and their inhibitors in potentially malignant and malignant lesions of the head and neck. J Biomed Sci 2010; 17: 10 (3-13).
103. Wang A, Rana S, Karumanchi SA. Preeclampsia: The role of angiogenic factors in its pathogenesis. Physiology 2009; 24: 147-158.
104. Carty DM, Delles C, Dominiczak AF. Novel biomarkers for predicting preeclampsia. Trends Cardiovasc Med 2008; 18: 186-194.